CAL101 is a first-in-class monoclonal antibody targeting S100A4, a DAMP protein implicated in severe, life-threatening fibrotic diseases CAL101 being investigated in Phase 2 IPF Study; enrollment ...

OSLO, Norway--(BUSINESS WIRE)--Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the ...

CAL101 is a first-in-class monoclonal antibody targeting S100A4, a damage-associated molecular pattern (DAMP) protein associated with serious and life-threatening fibrotic disorders Phase 2 AURORA ...

Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx), companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, today announced their ...

Calluna Pharma has concluded the Phase I clinical study of its lead product, CAL101, for fibrotic and fibro-inflammatory indications. CAL101 is a first-in-class monoclonal antibody (mAb) targeting the ...

Oxitope Pharma and Arxx Therapeutics have announced their merger to form Calluna Pharma, which has raised €75m in a series A financing, to develop novel therapies for immunological diseases. The new ...

Calluna Pharma AS has announced the successful completion of Phase 1 clinical trials for its lead drug candidate, CAL101, a first-in-class monoclonal antibody (mAb) targeting fibrotic and ...

The role of ericoid mycorrhizal colonization in competition between the dwarf shrub Calluna vulgaris and coarse grass Nardus stricta was investigated. Nardus was grown alone, or in competition with ...

1. Climate change and atmospheric deposition of nitrogen (N) affect the biodiversity patterns and functions of ecosystems world-wide. While many single-factor studies have quantified ecosystem ...

New company to complete multiple clinical proofs-of-concept, across programs Series A led by Forbion, with participation from Norwegian investors Sarsia, p53, and Investinor NAARDEN, The Netherlands & ...